RAS

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Retrieved on: 
Wednesday, January 17, 2024
Tumor microenvironment, Development, Death, Pancreatic cancer, Patient, Therapy, Cancer, Neoplasm, DNA, Pancreas, Standard of care, Survival, AMP, Poster, University, Lymphocyte, Risk, HLA, Safety, UCLA, Lymph, CA19-9, Immunization, University of California, PDAC, Research and development, Observation, Biopsy, Colorectal cancer, Nature Medicine, RAS, Pharmaceutical industry

The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).

Key Points: 
  • The poster describes AMPLIFY-7P, a Phase 1 and randomized Phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine, administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (“PDAC”).
  • “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.
  • AMPLIFY-7P is a Phase 1 and Phase 2 study of ELI-002 7P in patients with RAS mutated pancreatic and colorectal tumors after locoregional treatment.
  • A Phase 2 interim analysis is planned using group sequential design for control of overall alpha 0.10.

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Retrieved on: 
Monday, January 29, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Verastem Oncology, Patient, Accelerated approval (FDA), Toxicology, GLP, BIW, Part, Diagnosis, Safety, RAMP, Cancer, NSCLC, IND, Food, NDA, RAS, Lung cancer, FDA, Avutometinib, QD, Pancreatic cancer, Pharmaceutical industry

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.
  • “We have made significant progress in our commitment to advancing new solutions for RAS pathway-driven cancers and look forward to an exciting and catalyst-filled year ahead.
  • Safety and tolerability continued to be favorable and consistent with previously reported data.
  • Entered into a discovery and development collaboration with GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers.

Global Aquaculture Industry Growth Opportunities: Transformative Mega Trends Open the Way for Sustainable Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, January 19, 2024
Agriculture, Food Tech, Natural Resources, Sustainability, Environment, Technology, Food, Beverage, Retail, Water pollution, Disease, Water, Urbanization, Biosolids, Seafood, Aquaculture, Circular economy, Internet of things, RAS, Growth

The "Growth Opportunities for Sustainability and the Circular Economy in the Global Aquaculture Industry" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunities for Sustainability and the Circular Economy in the Global Aquaculture Industry" report has been added to ResearchAndMarkets.com's offering.
  • This report on global sustainability and the circular economy in the aquaculture industry analyzes the current and future growth potential of the aquaculture value chain from a sustainability point of view.
  • An environmentally beneficial way to feed and provide the world's population with protein products is through aquaculture.
  • The rapid growth of the aquaculture market is driven by escalating global demand for seafood, a burgeoning population, and diminishing wild fish stocks.

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Thursday, January 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, Verastem Oncology, Patient, Therapy, MAPK, DLT, AACR, RAMP, Cancer, Mutation, Food, Conference, Safety, FDA, Toxicity, ERK, Avutometinib, RAS, Pharmaceutical industry

“Receiving Fast Track Designation for the combination of avutometinib and sotorasib reinforces the importance of improving the depth of MAPK pathway inhibition to enhance tumor regression relative to KRAS G12C inhibition alone and the potential of the combination of avutometinib and sotorasib in KRAS G12C mutant locally advanced or metastatic NSCLC,” said Dan Paterson, President and CEO, Verastem Oncology.

Key Points: 
  • “Receiving Fast Track Designation for the combination of avutometinib and sotorasib reinforces the importance of improving the depth of MAPK pathway inhibition to enhance tumor regression relative to KRAS G12C inhibition alone and the potential of the combination of avutometinib and sotorasib in KRAS G12C mutant locally advanced or metastatic NSCLC,” said Dan Paterson, President and CEO, Verastem Oncology.
  • “Given that KRAS G12C is the most common KRAS mutation in NSCLC, the advancement of the combination is important in understanding potential new treatment approaches.
  • The pharmacokinetic profile of avutometinib in combination with sotorasib in the RAMP 203 trial was similar to results in monotherapy studies.
  • These initial RAMP 203 results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October, 2023.

PRISM MarketView Announces the Addition of Verastem to Emerging Women’s Health Index

Retrieved on: 
Friday, January 12, 2024
PRISM, Woman, Patient, Melanoma, Cancer, CDC, Cervical cancer, Investment, HPV, Breast, RAS

NEW YORK, Jan. 12, 2024 (GLOBE NEWSWIRE) -- In concert with Cervical Health Awareness Month, PRISM MarketView has added Verastem, Inc. , a biopharmaceutical company focused on the development and commercialization of new medicines for patients combating various types of cancer to its Emerging Women’s Health Index.

Key Points: 
  • NEW YORK, Jan. 12, 2024 (GLOBE NEWSWIRE) -- In concert with Cervical Health Awareness Month, PRISM MarketView has added Verastem, Inc. , a biopharmaceutical company focused on the development and commercialization of new medicines for patients combating various types of cancer to its Emerging Women’s Health Index.
  • The growing PRISM Emerging Women’s Health Index tracks small and micro-cap stocks that focus on a broad range of women’s health concerns.
  • After its debut in the PRISM Emerging Women’s Health Index , Verastem has been a positive contributor to the indices’ performance.
  • With its focus on aggressive cancers that often target women, Verastem is an ideal candidate for the PRISM Emerging Women’s Health Index.

SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Regeneron Pharmaceuticals, Initiate, Conference, AACR, Orange Book, MAPK, Amgen, IND, B-cell maturation antigen, FDA, EMA, BeiGene, EGFR, MAA, Pain, Multiple myeloma, NDA, BCMA, Therapy, Cancer, Investigational New Drug, Event, First grade, Standard of care, TEAD, Neoplasm, Plantar fibromatosis, European Medicines Agency, RAF, European Hematology Association, CD3, MEK, Webcast, NRAS, RAS, Patient, Panitumumab, Pharmaceutical industry

Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024.

Key Points: 
  • Ahead of the presentation, the Company highlighted its 2023 accomplishments and announced its anticipated key milestones for 2024.
  • These presentations demonstrated rapid, sustained and consistent improvements in pain and functional status in patients receiving OGSIVEO using multiple assessment tools.
  • Initiate Phase 1 trial of SW-682, SpringWorks’ TEAD inhibitor, in Hippo mutant solid tumors in the first half of 2024.
  • A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

Global Steerable Needles (Bevel-tip Flexible, Symmetric-tip) Market Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 5, 2024
Medical Devices, Health, Cleveland Clinic, EPFL, NCBI, Biopsy, Government, Brushed DC electric motor, Needle, Hospital, Cancer, DSM-IV codes, USD, Molecular Modeling Database, Growth, ARC, RAS, Cardiovascular disease, Medical device

The "Steerable Needles Market Size, Share & Trends Analysis Report By Type (Bevel-tip Flexible, Symmetric-tip), By Application (Biopsy, Tumor Ablation, Robotic Assisted Surgery), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Steerable Needles Market Size, Share & Trends Analysis Report By Type (Bevel-tip Flexible, Symmetric-tip), By Application (Biopsy, Tumor Ablation, Robotic Assisted Surgery), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Thus, an increasing number of robotic-assisted surgery (RAS) cases are anticipated to boost demand for steerable needles during the forecast period.
  • These advancements have led to the development of more precise and accurate steerable needles and steerable needles that are compatible with a wide range of imaging modalities.
  • This initiative will strengthen the adoption of newly launched steerable needles worldwide, thereby driving the market growth.

Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates

Retrieved on: 
Thursday, January 4, 2024
Food, IND, FDA, EGFR, Cetuximab, MBA, MD, Doctor of Philosophy, Therapy, Investigational New Drug, RAS, Patient, Food and Drug Administration, Pharmaceutical industry

RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, today announced progress across its pipeline of KRAS-directed drug candidates, including U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) application clearance for QTX3034, a multi-KRAS inhibitor with G12D-preferring activity (G12D+ multi-KRAS), enabling the initiation of a Phase 1 clinical trial in the first quarter of 2024. Additionally, QTX3046, a KRASG12D-selective inhibitor continues its advancement through IND-enabling activities positioning the company to file an IND in the first half of 2024. Further, the company has recently selected QTX3544, a multi-KRAS inhibitor with G12V-preferring activity (G12V+ multi-KRAS), as a development candidate, representing Quanta’s third KRAS inhibitor program.

Key Points: 
  • Additionally, QTX3046, a KRASG12D-selective inhibitor continues its advancement through IND-enabling activities positioning the company to file an IND in the first half of 2024.
  • Further, the company has recently selected QTX3544, a multi-KRAS inhibitor with G12V-preferring activity (G12V+ multi-KRAS), as a development candidate, representing Quanta’s third KRAS inhibitor program.
  • “Patients with KRASG12D-mutant cancers face a poor prognosis and no targeted therapy options.
  • QTX3034 is the first of our two G12D-focused clinical approaches with QTX3046 following in the first half of 2024.

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Retrieved on: 
Thursday, January 4, 2024
Diamond, Conference, AACR, Food, FDA, EGFR, Cancer, Therapy, Clinical trial, RAF, GBM, RAS, Patient, Pharmaceutical industry

CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today provided a corporate update outlining clinical development plans and anticipated corporate milestones for 2024.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, today provided a corporate update outlining clinical development plans and anticipated corporate milestones for 2024.
  • “In 2024, we anticipate key readouts from each of these programs, including Phase 2 data from BDTX-1535 in NSCLC.
  • Phase 2 data in second/third-line patients with EGFR mutant NSCLC are expected in the third quarter of 2024.
  • Results from this trial are expected to be presented at a medical meeting in the second quarter of 2024.

Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid (RGX-202)

Retrieved on: 
Thursday, January 4, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, SLC6A8, Merck Group, CRC, ESMO, Survival, Rasm, Health care, Colorectal cancer, FOLFIRI, Progression-free survival, Congress, Randomized controlled trial, Bevacizumab, Creatine, Merck, RAS, Patient, Safety, Head, Therapy, Pharmaceutical industry

“The data to date validates our belief in ompenaclid as a potential first-in-class therapy for advanced colorectal cancer and underscores the power of our proprietary target discovery platform RNA-DRIVEr™.

Key Points: 
  • “The data to date validates our belief in ompenaclid as a potential first-in-class therapy for advanced colorectal cancer and underscores the power of our proprietary target discovery platform RNA-DRIVEr™.
  • Furthermore, the parties agreed to collaborate on Inspirna’s SLC6A8 follow-on compounds for which Inspirna will retain US co-development and co-commercialization rights.
  • Ompenaclid was well-tolerated, with no dose-limiting toxicities observed in the dose-escalation cohort and combination safety profile comparable to FOLFIRI plus bevacizumab backbone treatment.
  • Inspirna has initiated a Phase 2 double-blind randomized controlled trial in 2L RAS mutant advanced or metastatic mCRC comparing ompenaclid versus placebo plus FOLFIRI and bevacizumab.